Third space sequestration increases toxicity of fludarabine--a case report.
Mahadevan
A
A
Department of Clinical Oncology, Mount Vernon Hospital, Centre for Cancer Treatment, Northwood, Middlesex, England.
Kanegaonkar
R
R
Hoskin
P J
PJ
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D004322:Drainage; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D010996:Pleural Effusion / Q000737:chemistry / Q000378:metabolism*; D018805:Sepsis / Q000209:etiology; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine